Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window

Impact of treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who had initiated antiretroviral therapy during the early phase of infection

(2019) Erin D Huiting et al.   JOURNAL OF INFECTIOUS DISEASES

Protein kinase C: perfectly balanced

(2018) Alexandra C. Newton   CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY

HIV latency is reversed by ACSS2-driven histone crotonylation

(2018) Guochun Jiang et al.   JOURNAL OF CLINICAL INVESTIGATION

The expanding role of prodrugs in contemporary drug design and development

(2018) Jarkko Rautio et al.   NATURE REVIEWS DRUG DISCOVERY

Bryostatin-1 alleviates experimental multiple sclerosis

(2018) Michael D. Kornberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy

(2018) So-Yon Lim et al.   Science Translational Medicine

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents

(2018) Matthew D. Marsden et al.   VIROLOGY

Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal

(2018) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

(2018) Erica N. Borducchi et al.   NATURE

T cell toxicity of HIV latency reversing agents

(2018) Manzhi Zhao et al.   PHARMACOLOGICAL RESEARCH

Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy

(2017) Angela Tsai et al.   JOURNAL OF VIROLOGY

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV

(2017) Paul A. Wender et al.   SCIENCE

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

(2017) Pengfei Wang et al.   Scientific Reports

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication

(2017) Matthew D. Marsden et al.   PLoS Pathogens

Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program

(2017) Seema T. Meloni et al.   AIDS Research and Therapy

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation

(2017) Brice J. Albert et al.   Scientific Reports

Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies

(2016) Omar Sued et al.   ADVANCED DRUG DELIVERY REVIEWS

Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons

(2016) Lene Ryom et al.   AIDS

Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

(2016) Carolina Gutiérrez et al.   AIDS

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

(2016) Adrian S. Ray et al.   ANTIVIRAL RESEARCH

Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo

(2016) Adam M. Spivak et al.   Retrovirology

Latency reversal and viral clearance to cure HIV-1

(2016) D. M. Margolis et al.   SCIENCE

Euphorbia Kansui Reactivates Latent HIV

(2016) Daniele C. Cary et al.   PLoS One

Function through Synthesis-Informed Design

(2015) Paul A. Wender et al.   ACCOUNTS OF CHEMICAL RESEARCH

Progress and challenges in the use of latent HIV-1 reactivating agents

(2015) Hong-tao Shang et al.   ACTA PHARMACOLOGICA SINICA

Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV Latency

(2015) Guochun Jiang et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Ex VivoBioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+T Cells from Aviremic Patients

(2015) Adam M. Spivak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tigliane Diterpenoids from the Euphorbiaceae and Thymelaeaceae Families

(2015) Hong-Bing Wang et al.   CHEMICAL REVIEWS

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

(2015) Guochun Jiang et al.   PLoS Pathogens

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

(2015) Ole S. Søgaard et al.   PLoS Pathogens

Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ–NF-κB signaling

(2014) Guochun Jiang et al.   AIDS

Euphorbia Diterpenes: Isolation, Structure, Biological Activity, and Synthesis (2008–2012)

(2014) Andrea Vasas et al.   CHEMICAL REVIEWS

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

(2014) Thomas A Rasmussen et al.   Lancet HIV

HIV/AIDS eradication

(2013) Matthew D. Marsden et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer

(2013) Gunnar Grue-Sørensen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo

(2013) E. J. Beans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bryostatin Improves Survival and Reduces Ischemic Brain Injury in Aged Rats After Acute Ischemic Stroke

(2013) Zhenjun Tan et al.   STROKE

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

(2012) N. M. Archin et al.   NATURE

Ingenol Mebutate Gel for Actinic Keratosis

(2012) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC- II depletion

(2011) V. Biberacher et al.   HAEMATOLOGICA

Prodrugs--from Serendipity to Rational Design

(2011) K. M. Huttunen et al.   PHARMACOLOGICAL REVIEWS

Antiretroviral drug supply challenges in the era of scaling up ART in Malawi

(2011) Erik J Schouten et al.   Journal of the International AIDS Society

Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency

(2010) Moises Perez et al.   CURRENT HIV RESEARCH

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

(2009) Mayte Coiras et al.   NATURE REVIEWS MICROBIOLOGY

Postischemic PKC activation rescues retrograde and anterograde long-term memory

(2009) M.-K. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

(2008)   LANCET

Expression of CD69 on T‐cell subsets in HIV‐1 disease

(2008) C. Pitsios et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV

(2008) P. A. Wender et al.   SCIENCE

Function-Oriented Synthesis, Step Economy, and Drug Design

(2007) Paul A. Wender et al.   ACCOUNTS OF CHEMICAL RESEARCH